Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of different bromide equilibrium times to measure extracellular water in athletes: Analysis before and after a 4-day intervention to increase water intake.

Clinical nutrition ESPEN·2026
Same author

Changes in Water Turnover and Its Components Over One Athletic Season: An Observational Study Among Athletes From Different Sports.

International journal of sport nutrition and exercise metabolism·2026
Same author

Sex Differences in Measures of Energy Expenditure and Body Composition in Young, Middle-Aged, and Older Adults.

Current developments in nutrition·2026
Same author

Measuring dietary intake among participants with a urea cycle disorder using standard diet records or a novel food photography app.

Molecular genetics and metabolism·2025
Same author

Energy expenditure and obesity across the economic spectrum.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Isotope Dilution for Measuring Total Energy Expenditure, Water Turnover, and Total Body Water in Athletes: A Systematic Review.

International journal of sport nutrition and exercise metabolism·2025
Same journal

Different approaches of strength-to-muscle mass ratio: impact on 24-month outcomes in patients with acute coronary syndrome.

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same journal

From scriptural reference to scientific evidence a critical review of the nutritional composition and functional food potential of foods described in classical Islamic texts.

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same journal

Integrating BIA-derived body composition parameters with GLIM criteria for survival prediction in patients with solid tumors.

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same journal

Polyunsaturated fatty acids in the prevention, treatment, and survival of breast cancer.

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same journal

Unpacking the eating pathways: The mediating roles of emotional eating and problem-solving skills in the relationship between childhood trauma and eating expectancies.

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same journal

Improving communication about dietary fats: development and validation of the Fats-Related Attitude Scale based on data from Brazil, China, Croatia, Poland, and Spain.

Nutrition (Burbank, Los Angeles County, Calif.)·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Exenatide and weight loss.

David P Bradley1, Roger Kulstad, Dale A Schoeller

  • 1Division of Endocrinology, University of Wisconsin, Madison, Wisconsin, USA.

Nutrition (Burbank, Los Angeles County, Calif.)
|February 16, 2010
PubMed
Summary
This summary is machine-generated.

Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, consistently leads to weight loss in clinical trials. While it affects energy intake and expenditure, the precise mechanisms require further investigation for obesity pharmacotherapy.

More Related Videos

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

Related Experiment Videos

Last Updated: Jun 16, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolism

Background:

  • Glucagon-like peptide-1 (GLP-1) is an incretin hormone regulating glucose-dependent insulin secretion.
  • Exenatide, a synthetic GLP-1 receptor agonist derived from lizard venom, offers prolonged receptor stimulation.
  • GLP-1 receptor agonists are explored for managing metabolic disorders and obesity.

Purpose of the Study:

  • To review exenatide-induced weight loss.
  • To summarize the mechanisms underlying exenatide's effects on body weight.
  • To discuss exenatide's potential role in obesity pharmacotherapy.

Main Methods:

  • Literature search on PubMed using terms 'exenatide' and 'weight loss'.
  • Secondary search using terms 'exenatide' and 'mechanisms' or 'actions'.

Main Results:

  • Clinical trials consistently report weight loss with exenatide treatment.
  • Exenatide enhances insulin secretion in a glucose-dependent manner.
  • Evidence suggests exenatide influences both energy intake and expenditure, though findings are debated.

Conclusions:

  • Exenatide treatment is associated with significant weight loss.
  • The exact contribution of reduced energy intake versus increased energy expenditure to weight loss remains unclear.
  • Further research is recommended to elucidate exenatide's weight loss mechanisms for obesity treatment.